ICER prices gene therapies for sickle cell disease at $1.9 million

13 April 2023
icer_big

A  draft evidence report from Boston, USA-based watchdog the Institute for Clinical and Economic Review (ICER) suggests a cost-effective price of up to $1.9 million for new sickle cell disease (SCD) therapies.

The research focuses on two experimental gene therapies - exagamglogene autotemcel (exa-cel), from Swiss gene editing specialist CRISPR Therapeutics (Nasdaq: CRSP) and partner Vertex Pharmaceutical (Nasdaq: VRTX), and lovotibeglogene autotemcel (lovo-cel), from bluebird bio (Nasdaq: BLUE).

The former has already been submitted to the US Food and Drug Administration for regulatory consideration, while bluebird is expected to submit its option to the US regulator imminently.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology